The estimated Net Worth of David W J Mcgirr is at least $488 Tausend dollars as of 21 June 2024. Mr. Mcgirr owns over 3,000 units of Insmed Inc stock worth over $218,280 and over the last 11 years he sold INSM stock worth over $0. In addition, he makes $270,000 as Independent Director at Insmed Inc.
David has made over 1 trades of the Insmed Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of INSM stock worth $218,280 on 21 June 2024.
The largest trade he's ever made was exercising 3,000 units of Insmed Inc stock on 21 June 2024 worth over $218,280. On average, David trades about 94 units every 0 days since 2013. As of 21 June 2024 he still owns at least 3,000 units of Insmed Inc stock.
You can see the complete history of Mr. Mcgirr stock trades at the bottom of the page.
David W. J. McGirr is an Independent Director of Insmed Incorporated Since october 2013. From March 2013 to June 2014, Mr. McGirr served as a Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), a biopharmaceutical company that was acquired by Merck and Co. in December of 2014. He previously served as Senior Vice President and Chief Financial Officer from November 2002 to March 2013, and as Treasurer from 2002 until 2003. From 1999 to 2002, Mr. McGirr was the President and Chief Operating Officer of hippo inc, a venture-financed internet technology company, and was also a member the hippo inc. board of directors from 1999 to 2003. From 1996 to 1999, he was the President of GAB Robins North America, Inc., a risk management company, serving also as Chief Executive Officer from 1997 to 1999. Mr. McGirr was a private equity investor from 1995 to 1996. From 1978 to 1995, Mr. McGirr served in various positions within the S.G. Warburg Group, ultimately as Chief Financial Officer, Chief Administrative Officer and Managing Director of S.G. Warburg & Co., Inc., a position held from 1992 to 1995. Mr. McGirr serves on the board of directors of Relypsa, Inc. (Nasdaq: RLYP), a clinical-stage biopharmaceutical company, and Roka Bioscience, Inc. (Nasdaq: ROKA), a molecular diagnostics company. Mr. McGirr holds a Bachelor of Science degree in civil engineering from the University of Glasgow and a Master of Business Administration degree from The Wharton School at the University of Pennsylvania. Mr. McGirr has more than 30 years of experience as a senior financial executive, including nearly 12 years at Cubist, during which the company secured a number of product approvals and launched these products across multiple markets.
As the Independent Director of Insmed Inc, the total compensation of David McGirr at Insmed Inc is $270,000. There are 14 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of $7,175,090.
David McGirr is 65, he's been the Independent Director of Insmed Inc since 2013. There are 3 older and 20 younger executives at Insmed Inc. The oldest executive at Insmed Inc is Steinar Engelsen, 70, who is the Independent Director.
David's mailing address filed with the SEC is 222 BERKELEY STREET, 12TH FLOOR, , BOSTON, MA, 02116.
Over the last 22 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis und Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
Insmed Inc executives and other stock owners filed with the SEC include: